The research facility includes 30-bed, Phase 1 unit and multiple outpatient clinical examination rooms.
As part of the company’s Research Clinics Division, the new facility is also used to conduct dermatological safety studies and will join three of its other clinics in northern New Jersey.
TKL Research president and CEO Jon Anderson said the Fair Lawn research facility will enable the company to meet the increased demand for its services in the diseased-state populations for Phase 1 clinical trials.
In 2006, the company moved its CRO operations to Rochelle Park, New Jersey, and in 2010 expanded its European capabilities with clinical operations in Münster, Germany.
"These moves, as well as the construction of our new facility in Fair Lawn, will help us continue to deliver exceptional services to our clients that give them a competitive edge and accelerated enrollment," Anderson added.
The company’s new facility is expected to be ready by early 2014.